Liquid chromatographic determination of lumiracoxib in pharmaceutical formulations.
A stability-indicating reversed-phase liquid chromatography (LC) method was developed and validated for the determination of lumiracoxib in pharmaceutical formulations. The LC method was carried out on a Synergi fusion C(18) column (150 mmx4.6mm), maintained at 30 degrees C. The mobile phase was composed of phosphoric acid (25 mM; pH 3.0)/acetonitrile (40:60, v/v), run at a flow rate of 1.0mL/min, and detection at 272nm. The chromatographic separation was obtained within 10 min and it was linear in the concentration range of 10-100 microg/mL (r(2)=0.9999). Validation parameters such as the specificity, linearity, precision, accuracy, and robustness were evaluated, giving results within the acceptable range. Stress studies were carried out and no interference of the degradation products was detected. Moreover, the proposed method was successfully applied for the assay of lumiracoxib in pharmaceutical formulations.